We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

6 hedge funds and large institutions have $5.23M invested in Cellectar Biosciences in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
6
Holders Change
+6
Holders Change %
–
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
+$6.39M
2
SM
Sabby Management
Florida
+$2.07M
3
CAM
Cormorant Asset Management
Massachusetts
+$1.55M
4
SC
Sophrosyne Capital
New York
+$518K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$259K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AWMDMG
1
Austin W. Marxe & David M. Greenhouse
New York
$3.3M +$6.39M +74 New
CAM
2
Cormorant Asset Management
Massachusetts
$1.18M +$1.55M +18 New
SC
3
Sophrosyne Capital
New York
$389K +$518K +6 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$224K +$259K +3 New
BA
5
Bard Associates
Illinois
$95K +$86.3K +1 New
KCM
6
Knoll Capital Management
Florida
$33K – – –
Morgan Stanley
7
Morgan Stanley
New York
$6K – – –
U
8
UBS
Switzerland
$6K – – –
SM
9
Sabby Management
Florida
$1.66K +$2.07M +24 New

CLRB Hedge Fund Activity: Q3 2014 in Review

6 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2014, worth a combined $5.23M.

Buyers outnumbered sellers: 6 funds opened new CLRB positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Austin W. Marxe & David M. Greenhouse, opening a new position worth an estimated $6.39M.

  • 6 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2014, up from 0 in Q2 2014.
  • Funds reported $5.23M of Cellectar Biosciences stock for Q3 2014.
  • 6 funds opened new Cellectar Biosciences positions in Q3 2014 and 0 closed out, a net change of +6 holders.
  • The largest Cellectar Biosciences buyer in Q3 2014 was Austin W. Marxe & David M. Greenhouse, an estimated $6.39M added.

Based on aggregated 13F filings for Q3 2014.